Clostridioides difficile antibiotic, DIFICID, receives FDA approval for treating children aged six months and older

Merck announced today the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for DIFICID(R) (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older. DIFICID is a macrolide antibacterial ["]

The post Clostridioides difficile antibiotic, DIFICID, receives FDA approval for treating children aged six months and older appeared first on Outbreak News Today.